Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
Iovance: Down And Rebound
09:34am, Sunday, 30'th May 2021
As the FDA is requesting additional potency assay data, the potential lifileucel approval for melanoma will be delayed. Despite recent uncertainty, Iovance made a huge comeback due to the superb data
Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)
01:46am, Monday, 24'th May 2021
Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc (NASDAQ: IOVA) will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immun
Here's Why Everyone's Talking About Iovance Biotherapeutics
06:47am, Saturday, 22'nd May 2021
The CEO's unexplained departure has left investors scratching their heads.
Cathie Wood's ARK Invest Buys Over 1 Million Shares of Iovance Bio
10:05am, Friday, 21'st May 2021
A couple of the ARK exchange-traded funds run by ETF star Cathie Wood made huge purchases on Thursday.
SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Hagens Berman urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) investors with significant losses to submit your losses now. The firm is investigating p
Iovance Shares Jump After Lifileucel Achieves 86% Response Rate In Melanoma Trial
12:20pm, Thursday, 20'th May 2021
Yesterday the FDA asked Iovance Biotherapeutics Inc (NASDAQ: IOVA) for more data on the assays for lifileucel US application. Now the company announced additional clinical data for lifileucel al
Merck, Micron, Nvidia, Target and More Thursday Afternoon Analyst Calls
11:43am, Thursday, 20'th May 2021
With the trading day almost halfway over, the markets had made a handy recovery on Thursday, bouncing off the lows of last week.
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
11:17am, Thursday, 20'th May 2021
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
Ademi LLP Investigates Claims of Securities Fraud against Iovance Biotherapeutics, Inc.
10:40am, Thursday, 20'th May 2021
MILWAUKEE, May 20, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Iovance (NASDAQ: IOVA). The investigation results from inaccurate statements Iovance may h
Is the Options Market Predicting a Spike in Iovance Biotherapeutics (IOVA) Stock?
09:46am, Thursday, 20'th May 2021
Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.
The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors
10:52pm, Wednesday, 19'th May 2021
LOS ANGELES--(BUSINESS WIRE)---- $IOVA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Iovance Biotherapeutics, Inc. (IOVA) on Behalf of Investors
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting
05:04pm, Wednesday, 19'th May 2021
86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
Additional Assay Data Holdup Delays Iovance's Lifileucel Filing Again, CEO Resigns; Shares Plunge
03:20pm, Wednesday, 19'th May 2021
In a brief statement, Iovance Biotherapeutics Inc (NASDAQ: IOVA) company divulged that the FDA wants to see more data on the assays used to ensure each batch of its tumor-infiltrating lymphocyte t
Why Iovance Biotherapeutics Stock Is Crashing Today
12:17pm, Wednesday, 19'th May 2021
The company is delaying the FDA approval filing for cell therapy lifileucel.
